AGT and endothelial dysfunction: The use of angiotensin-converting enzyme inhibitors decreases atherogenesis by inhibiting the conversion of angiotensin I to angiotensin II, increasing nitric oxide levels, improving endothelial dysfunction, increasing bradykinin levels, and decreasing muscle proliferation.